SpectraCure has been approved a grant from EU of € 125,000
SpectraCure has been approved a grant from EU of € 125,000 for an industrialization project for the company's product, for the treatment of prostate cancer with interstitial photodynamic treatment (PDT). The grant is approved as part of MedPhab, a so-called "pilot production line", financed through grants from the EU's Horizon 2020 program.In the project, SpectraCure will collaborate with Philips Innovation Services in the Netherlands, and CSEM SA in Switzerland. The aim of the project is to adapt SpectraCure's system for PDT treatment, the P18 system, for series production, by shortening